BCL6 and neoplasm: The sustained increase of Bcl-6 to T-bet secondary to the deletion of T-bet in CD4+ T cells was deleterious to anti-tumor responses, and reduced Bcl-6 expression at the early stage of treatment only produced some survival benefit.